Apyx Medical Corporation · NASDAQ:APYX
Apyx Medical — Investor Presentation (March 2025)
24 slides from Apyx Medical's investor presentation, March 2025
Slide 1: Investor Presentation: The Leader in Surgical Aesthetics
INVESTOR PRESENTATION THE LEADER IN SURGICAL AESTHETICS March 2025
Slide 2: Cautionary Statements
CAUTIONARY STATEMENTS Forward Looking Statements Certain matters discussed in this presentation and oral statements made from time to time by representatives of the Company may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and the Fe
Slide 3: A Leader in Surgical Aesthetics
A LEADER IN SURGICAL AESTHETICS Leading developer of innovative surgical technologies used 01 Recently developed the AYON body contouring system, 04 in minimally invasive aesthetic surgical procedures, most which is designed to dominate the surgical suite; notably post-liposuction, which remains the
Slide 4: Rapidly Shifting Medical Aesthetics Market
RAPIDLY SHIFTING MEDICAL AESTHETICS MARKET ▲ GLP-1 drugs resulting in significant patient weight loss are impacting legacy treatments ▲ Noninvasive procedures to not offer durable or transformative results for patients ▲ Med Spa revenue down 30% and overall liposuction procedures down ~5% since FDA
Slide 5: The Loose Skin Revolution
THE LOOSE SKIN REVOLUTION More broadly, half of consumers (50%) would consider a treatment to reduce loose skin because they want to look and feel more like themselves. Reasons why the target demographic might consider a treatment that reduces loose skin* Other I saw a celebrity or influencer have a
Slide 6: Multi Billion Dollar Global Market Opportunity
MULTI BILLION DOLLAR GLOBAL MARKET OPPORTUNITY Generators ~$2.3B1 Generators ~$8.5B3 Market opportunity in U.S. Market opportunity worldwide Handpieces ~$750M2 Handpieces ~$1.9B4 Annual market opportunity in U.S. Annual market opportunity worldwide ~15,000 Total estimated Plastic surgeons, cosmetic
Slide 7: U.S. Market Opportunity – Plus $1B+ with AYON
U.S. MARKET OPPORTUNITY – PLUS $1B+ WITH AYON GENERATORS HANDPIECES ~$2.3B ~$750M Potential market opportunity Potential annual market opportunity ~$550M2 ~15,0001 > 1 million annual surgical procedures plastic surgeons, • ~384K annual liposuction procedures cosmetic surgeons, & • ~700K annual surgi
Slide 8: AYON: Revolutionizing Body Contouring
AYON: REVOLUTIONIZING BODY CONTOURING All-in-One Platform: Precise, Superior Results: AYON seamlessly integrates Ultrasound- AYON’s integrated Lipo Intelligent Assisted Liposuction (UAL), Power-Assisted Frequency Tracking (LIFT) Technology Liposuction (PAL), Renuvion, infiltration, offers real-time
Slide 9: Beneath the Surface
BENEATH THE SURFACE CUTTING-EDGE 3-IN-1 ENERGY SYSTEM: RENUVION® ENERGY AND FULL MONOPOLAR AND BIPOLAR FUNCTIONALITY INNOVATIVE FEATURES Adaptive home screen CLOUD Intuitive touch screen CONNECTIVITY Presets by area Procedural information ADVANCED recording and reporting GAS SYSTEM Remote system dia
Slide 10: Renuvion: Transforming Physicians' Practices and Patients' Lives
RENUVION: TRANSFORMING PHYSICIANS’ PRACTICES AND PATIENTS’ LIVES Apyx’s primary product, Renuvion is the result of Plastic and aesthetic surgeons Renuvion®, is a minimally extensive scientific research and are providing weight loss invasive technology that takes clinical development. Because medicat
Slide 11: How Renuvion Works
HOW RENUVION Handpiece inserted sub-dermally WORKS Renuvion® utilizes a unique combination of helium plasma and proprietary radiofrequency Contract skin via direct energy applied via a single-use heating wand inserted under the skin. The energy contracts collagen fibers, pulling the skin closer to t
Slide 12: Real Results
REAL RESULTS PATIENT 51-YEAR-OLD MALE PROCEDURE TYPE LIPOSUCTION + RENUVION® AMOUNT OF FAT REMOVED 100 ml BEFORE 5.5 MONTHS POST-OP* Photos courtesy of Grant Hamlet, MD. *Patient gained 14 lbs since initial procedure 12
Slide 13: Real Results: Back Case Example #1
REAL RESULTS PATIENT BACK CASE EXAMPLE #1 33-YEAR-OLD FEMALE PROCEDURE TYPE LIPOSUCTION + RENUVION® AMOUNT OF FAT REMOVED 1,750 cc BEFORE 2.5 MONTHS POST-OP Photos courtesy of J Kevin Duplechain, MD. Disclosure: The patient shown in the pictures above is an employee of Apyx Medical. 13
Slide 14: Driving Patient Demand + Optimizing Provider Results
DRIVING PATIENT DEMAND + OPTIMIZING PROVIDER RESULTS Renuvion DTC & Physician Marketing Strategy INFLUENCER AMPLIFY AWARNESS ADRESSING THE LOOSE PRACTICE GROWTH + MARKETING IMPACT THROUGH KEY EVENTS SKIN EPIDEMIC ENHANCING RESULTS Leveraging partnerships with Participating in premier lifestyle Launc
Slide 15: Renuvion in the News in 2024
RENUVION IN THE NEWS IN 2024 15
Slide 16: Regulatory Competitive Advantages
REGULATORY COMPETITIVE ADVANTAGES The only device that is FDA- The only device that is FDA-cleared for cleared for use after liposuction contracting subcutaneous soft tissue as needed, anywhere on the body Strong IP protection, including 51 The only device that is FDA-cleared for issued and pending
Slide 17: Global Presence
GLOBAL PRESENCE Driving Driving growth growth bybyexpanding expanding customerbase customer baseand andincreasing increasing utilization from existing accounts utilization from existing accounts Sofia, Bulgaria Manufacturing facility We are also registered to sell our We are also registered to sell
Slide 18: Strategic Initiatives Announced in Q4 2024
STRATEGIC INITIATIVES ANNOUNCED IN Q4 2024 ▲ Completed a registered direct offering with net proceeds of $7.0 million with a healthcare-focused fund ▲ Amended credit agreement with Perceptive Credit Holdings IV, LP: ▲ Significantly reduce the trailing twelve-month Advanced Energy revenue covenants ▲
Slide 19: 2025 Financial Guidance
2025 FINANCIAL GUIDANCE ▲ Total revenue expected in the range of $47.6 million to $49.0 million, compared to $48.1 million for the year ended December 31, 2024 • Advanced Energy revenue is expected to be in the range of $39.6 million to $41.0 million, compared to $38.6 million • OEM revenue is expec
Slide 20: 2025 Company Objectives
2025 COMPANY OBJECTIVES Prepare for planned launch of AYON in the second 01 04 half of 2025, pending clearance, and capitalize on Continue to develop network outside of U.S. increased demand for market tailwinds related to GLP-1 drugs 02 05 Continue to expand adoption of Renuvion® as the Continue to
Slide 21: Q&A Office Locations
Q&A Office Locations APYX MEDICAL CORPORATION 5115 Ulmerton Road • Clearwater, FL 33760-4004 • USA APYX BULGARIA Manufacturing Facility and European Authorized Service Center 21
Slide 22: Platform Equipment and Single-Use Handpieces
PLATFORM EQUIPMENT AND SINGLE-USE HANDPIECES Renuvion ‘Apyx One’ Generator Platform and Handpieces 22
Slide 23: Compelling Clinical and Real-World Evidence
COMPELLING CLINICAL AND REAL-WORLD EVIDENCE The safety and efficacy of Renuvion is supported by more than 90 published clinical papers, abstracts and posters, as well as 2 multi-site IDE clinical studies. 23 Clinical Publications at: https://physicians.renuvion.com/library/
Slide 24: The Apyx One Console
THE APYX ONE CONSOLE ADAPTIVE/ PROCEDURAL CLOUD DATA SHARING/ SYSTEM GAS VOLUME SCREENS INTUITIVE TOUCH PRESETS CONNECTIVITY UPGRADES DIAGNOSTICS MONITOR 24